and the depth of experience and long-term track record that supports each element of the strategy. The Fund’s primary focus will be on investments in the Biopharmaceutical and Information Convergence sectors, with a secondary focus on Medical Devices and Biological Research Tools & Infrastructure. Investments will be predominantly in the U.S., but